<p>CARsgen Therapeutics Holdings Ltd. announced a profit alert indicating an estimated reduction in loss for the year ended December 31, 2025. Based on a preliminary assessment of unaudited management accounts, the company attributes the improved business performance in part to the commercialisation of zevorcabtagene autoleucel and the acceptance of a New Drug Application (NDA). This reflects a significant positive variation compared to previous periods, as the company anticipates a narrowed loss for the reporting year. The detailed annual results are expected to be published by early March 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260126-12000885), on January 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

IDNA

SBIO

Reuters

iShares Genomics Immunology and Healthcare ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Health Care Select Sector SPDR

Wisdomtree BioRevolution Fund ETF

iShares Global Healthcare

VG Health

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Ark Innovation ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

CRISPR Therap

iShares Biotechnology ETF

Franklin Genomic Adv ETF

CARsgen Therapeutics forecasts sharp reduction in annual net loss for 2025